Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Silencing of X-linked Inhibitor of Apoptosis (XIAP) Decreases Gemcitabine Resistance of Pancreatic Cancer Cells

SHAILESH V. SHRIKHANDE, JÖRG KLEEFF, HANY KAYED, SHEREEN KELEG, CAROLIN REISER, THOMAS GIESE, MARKUS W. BÜCHLER, IRENE ESPOSITO and HELMUT FRIESS
Anticancer Research September 2006, 26 (5A) 3265-3273;
SHAILESH V. SHRIKHANDE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JÖRG KLEEFF
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: joerg_kleeff{at}med.uni-heidelberg.de
HANY KAYED
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHEREEN KELEG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CAROLIN REISER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THOMAS GIESE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARKUS W. BÜCHLER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IRENE ESPOSITO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HELMUT FRIESS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 26 no. 5A 3265-3273
PMID 
17094439

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received June 16, 2006
  • Accepted July 13, 2006
  • Published online September 1, 2006.

Copyright & Usage 
Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. SHAILESH V. SHRIKHANDE1,2,
  2. JÖRG KLEEFF1,
  3. HANY KAYED1,
  4. SHEREEN KELEG1,
  5. CAROLIN REISER1,
  6. THOMAS GIESE3,
  7. MARKUS W. BÜCHLER1,
  8. IRENE ESPOSITO4 and
  9. HELMUT FRIESS1
  1. 1Department of General Surgery, University of Heidelberg, Heidelberg, Germany
  2. 2Department of Gastrointestinal Surgical Oncology, Tata Memorial Hospital, Mumbai, India
  3. 3Institute of Immunology, University of Heidelberg, Heidelberg, Germany
  4. 4Institute of Pathology, University of Heidelberg, Heidelberg, Germany
  1. Correspondence to: Jörg Kleeff, MD, Department of General Surgery, University of Heidelberg, 110, Im Neuenheimer Feld, 69120 Heidelberg, Germany. Tel: + 49 6221 56 4860, Fax: + 49 6221 56 6903, e-mail: joerg_kleeff{at}med.uni-heidelberg.de

Statistics from Altmetric.com

Cited By...

  • 55 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 26, Issue 5A
September-October 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Silencing of X-linked Inhibitor of Apoptosis (XIAP) Decreases Gemcitabine Resistance of Pancreatic Cancer Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Silencing of X-linked Inhibitor of Apoptosis (XIAP) Decreases Gemcitabine Resistance of Pancreatic Cancer Cells
SHAILESH V. SHRIKHANDE, JÖRG KLEEFF, HANY KAYED, SHEREEN KELEG, CAROLIN REISER, THOMAS GIESE, MARKUS W. BÜCHLER, IRENE ESPOSITO, HELMUT FRIESS
Anticancer Research Sep 2006, 26 (5A) 3265-3273;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Silencing of X-linked Inhibitor of Apoptosis (XIAP) Decreases Gemcitabine Resistance of Pancreatic Cancer Cells
SHAILESH V. SHRIKHANDE, JÖRG KLEEFF, HANY KAYED, SHEREEN KELEG, CAROLIN REISER, THOMAS GIESE, MARKUS W. BÜCHLER, IRENE ESPOSITO, HELMUT FRIESS
Anticancer Research Sep 2006, 26 (5A) 3265-3273;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
  • Z-360 Suppresses Tumor Growth in MIA PaCa-2-bearing Mice via Inhibition of Gastrin-induced Anti-Apoptotic Effects
  • Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer
  • CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
  • Vitamin E {delta}-Tocotrienol Augments the Antitumor Activity of Gemcitabine and Suppresses Constitutive NF-{kappa}B Activation in Pancreatic Cancer
  • Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic Cancer
  • Regulation of Colorectal Cancer Cell Apoptosis by the n-3 Polyunsaturated Fatty Acids Docosahexaenoic and Eicosapentaenoic
  • Google Scholar

More in this TOC Section

  • Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines
  • Enzalutamide Enhanced Honokiol-induced Apoptotic Insults to Drug-resistant Glioblastoma Cells via an Intrinsic Bak-mitochondrion-caspase Cascade Mechanism
  • Milk Extracellular Vesicle–mediated Delivery of siPRNP Suppresses Growth and Wound Closure in PC-3M Prostate Cancer Cells
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire